Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SD6V
|
|||
| Former ID |
DIB005452
|
|||
| Drug Name |
CFZ533
|
|||
| Indication | Graves disease [ICD-11: 5A02.0; ICD-10: E05.0, H06.2] | Phase 2 | [1] | |
| Myasthenia gravis [ICD-11: 8C6Y; ICD-10: G70.0; ICD-9: 358] | Phase 2 | [1], [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [3] | ||
| Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0] | Phase 2 | [1] | ||
| Company |
Novartis pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02291029) Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sj ren's Syndrome. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.